Drug intelligence / Profile preview

MOH-A5

Development stage: Preclinical
Lead developer: Multiomic Health
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

MOH-A5 is a preclinical therapeutic candidate being developed by Multiomic Health in partnership with Alloy Therapeutics for the treatment of chronic kidney disease (CKD). The program specifically targets kidney inflammation and fibrosis across multiple etiologies. MOH-A5 was identified using Multiomic Health's precision medicine platform, which utilizes multi-omics data to stratify patient populations and identify disease-driving mechanisms. As of 2024, the asset is in the in vitro and in vivo validation stage of preclinical development. The partnership with Alloy Therapeutics suggests the drug is likely a human monoclonal antibody discovered via Alloy's ATX-Gx platform.

Beyond the preview

Go deeper on MOH-A5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOH-A5.

Explore the full profile